Urinary metabonomics elucidate the therapeutic mechanism of Orthosiphon stamineus in mouse crystal-induced kidney injury

Journal of Ethnopharmacology

Volumn 166, Issue , 2015, Pages 323-332

  Gao, Songyan ^a   Chen, Wei ^b   Peng, Zhongjiang ^b   Li, Na ^a   Su, Li ^a   Lv, Diya ^a   Li, Ling ^a   Lin, Qishan ^c   Dong, Xin ^a   Guo, Zhiyong ^b   Lou, Ziyang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Biomarker discovery; Calcium oxalatecrystal; Metabonomics; Orthosiphon stamineus; UHPLC Q TOF MS

Indexed keywords

AMINO ACID; ANTIUROLITHIASIS AGENT; BIOLOGICAL MARKER; CALCIUM OXALATE; CHOLINE; HERBACEOUS AGENT; HYPOTAURINE; ORTHOSIPHON STAMINEUS EXTRACT; PHARMACOLOGY; PLANT EXTRACT; TAURINE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICS; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; CHINESE MEDICINE; CITRIC ACID CYCLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; ENERGY METABOLISM; ETHNOPHARMACOLOGY; HISTOPATHOLOGY; KIDNEY; KIDNEY DISEASES; KIDNEY INJURY; MALE; METABOLISM; METABOLOME; METABOLOMICS; METABONOMICS; MOUSE; NONHUMAN; ORTHOSIPHON; ORTHOSIPHON STAMINEUS; PARTIAL LEAST SQUARES REGRESSION; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PURINE METABOLISM; RENAL PROTECTION; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINE; UROLITHIASIS;

ANIMALS; BIOMARKERS; CALCIUM OXALATE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODELS, ANIMAL; DRUG EFFECTS; DRUG THERAPY; DRUGS, CHINESE HERBAL; ETHNOPHARMACOLOGY; KIDNEY; KIDNEY DISEASES; MALE; MEDICINE, CHINESE TRADITIONAL; METABOLISM; METABOLOME; METABOLOMICS; METHODS; MICE; MICE, INBRED C57BL; ORTHOSIPHON; PHARMACOLOGY; URINE;

MUS; ORTHOSIPHON STAMINEUS;

EID: 84964239517     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.03.025     Document Type: Article

References (37)

1. W. Akanae, M. Tsujihata, I. Yoshioka, N. Nonomura, and A. Okuyama Orthosiphon grandiflorum hasaprotective effect in a calcium oxalate stone forming rat model Urol. Res. 38 2010 89 96
2. M.A. Al-Kahtani Renal damage mediated by oxidative stress in mice treated with aluminium chloride: protective effects of taurine J. Biol. Sci. 10 2010 584 595
3. M. Amato, M. Lusini, and F. Nelli Epidemiology of nephrolithiasis today Urol. Int. 72 2004 1 5
4. O.Z. Ameer, I.M. Salman, M.Z. Asmawi, Z.O. Ibraheem, and M.F. Yam Orthosiphon stamineus: traditional uses, phytochemistry, pharmacology, and toxicology J. Med. Food 15 2012 678 690
5. R. Ando, T. Nagaya, S. Suzuki, H. Takahashi, M. Kawai, A. Okada, T. Yasui, Y. Kubota, Y. Umemoto, K. Tozawa, and K. Kohri Kidney stone formation is positively associated with conventional risk factors for coronary heart disease in Japanese men J. Urol. 189 2013 1340 1346
6. Y. Boirie, R. Albright, M. Bigelow, and K.S. Nair Impairment of phenylalanine conversion to tyrosine in end-stage renal disease causing tyrosine deficiency Kidney Int. 66 2004 591 596
7. E.C. Chan, K.K. Pasikanti, and J.K. Nicholson Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry Nat. Protoc. 6 2011 1483 1499
8. F. Domingos, and A. Serra Nephrolithiasis is associated with an increased prevalence of cardiovascular disease Nephrol. Dial. Transplant. 26 2011 864 868
9. J.D. Fernstrom, and M.H. Fernstrom Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain J. Nutr. 137 2007 1539S 1547S
10. X. Guan, G. Dei-Anane, R. Liang, M.L. Gross, A. Nickkholgh, M. Kern, J. Ludwig, M. Zeier, M.W. Büchler, and J. Schmidt Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation J. Surg. Res. 146 2008 127 134
11. Q. Huang, Y. Tan, P. Yin, G. Ye, P. Gao, X. Lu, H. Wang, and G. Xu Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics Cancer Res. 73 2013 4992 5002
12. C. Indiveri, L. Pochini, F. Oppedisano, and A. Tonazzi The carnitine transporter network: interactions with drugs Curr. Chem. Biol. 4 2010 108 123
13. R.J. Johnson, L.G. Sanchez-Lozada, M. Mazzali, D.I. Feig, M. Kanbay, and Y.Y. Sautin What are the key arguments against uric acid as a true risk factor for hypertension? Hypertension 61 2013 948 951
14. M.D. Kerai, C.J. Waterfield, S.H. Kenyon, D.S. Asker, and J.A. Timbrell Reversal of ethanol-induced hepatic steatosis and lipid peroxidation by taurine: a study in rats Alcohol Alcohol. 34 1999 529 541
15. C.Y. Li, Y.L. Deng, and B.H. Sun Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis Urol. Res. 37 2009 211 220
16. D.E. Matthews An overview of phenylalanine and tyrosine kinetics in humans J. Nutr. 137 2007 1549S 1555S discussion 1573S-1575S
17. W.J. Murphy, A. Steiber, G.C. Connery, J. Carder, L. Spry, and C. Hoppel Altered carnitine metabolism in dialysis patients with reduced physical function may be due to dysfunctional fatty acid oxidation Nephrol. Dial. Transplant. 27 2012 304 310
18. A. Okada, S. Nomura, Y. Higashibata, M. Hirose, B. Gao, M. Yoshimura, Y. Itoh, T. Yasui, K. Tozawa, and K. Kohri Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection Urol. Res. 35 2007 89 99
19. A. Okada, T. Yasui, S. Hamamoto, M. Hirose, Y. Kubota, Y. Itoh, K. Tozawa, Y. Hayashi, and K. Kohri Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity J. Bone Miner. Res. 24 2009 908 924
20. Paras K. Patel, Manish A. Patel, Bhavin A. Vyas, Dinesh R. Shah, and Tejal R. Gandhi Antiurolithiatic activity of saponin rich fraction from the fruits of Solanum xanthocarpum Schrad. & Wendl. (Solanaceae) against ethylene glycol induced urolithiasis in rats J. Ethnopharmacol. 144 2012 160 170
21. F. Romero, M. Perez, M. Chavez, G. Parra, and P. Durante Effect of uric acid on gentamicin-induced nephrotoxicity in rats - role of matrix metalloproteinases 2 and 9 Basic Clin. Pharmacol. Toxicol. 105 2009 416 424
22. A.D. Rule, E.J. Bergstralh, L.J. Melton, X. Li, A.L. Weaver, and J.C. Lieske Kidney stones and the risk for chronic kidney disease Clin. J. Am. Soc. Nephrol. 4 2009 804 811
23. A.D. Rule, A.E. Krambeck, and J.C. Lieske Chronic kidney disease in kidney stone formers Clin. J. Am. Soc. Nephrol. 6 2011 2069 2075
24. A.D. Rule, V.L. Roger, L.J. Melton, E.J. Bergstralh, X. Li, P.A. Peyser, A.E. Krambeck, and J.C. Lieske Kidney stones associate with increased risk for myocardial infarction J. Am. Soc. Nephrol. 21 2010 1641 1644
25. M.M. Sayed-Ahmed Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model Clin. Exp. Nephrol. 14 2010 418 426
26. M. Shimada, R.J. Johnson, W.S. May Jr., V. Lingegowda, P. Sood, T. Nakagawa, Q.C. Van, B. Dass, and A.A. Ejaz A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome Nephrol. Dial. Transplant. 24 2009 2960 2964
27. A.K. Smilde, M.J. van der Werf, S. Bijlsma, B.J. van der Werff-van der Vat, and R.H. Jellema Fusion of mass spectrometry-based metabolomics data Anal. Chem. 77 2005 6729 6736
28. C.A. Smith, E.J. Want, G. O'Maille, R. Abagyan, and G. Siuzdak XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification Anal. Chem. 78 2006 779 787
29. K. Taguchi, A. Okada, H. Kitamura, T. Yasui, T. Naiki, S. Hamamoto, R. Ando, K. Mizuno, N. Kawai, K. Tozawa, K. Asano, M. Tanaka, I. Miyoshi, and K. Kohri Colony-stimulating factor-1 signaling suppresses renal crystal formation J. Am. Soc. Nephrol. 25 2014 1680 1697
30. G. Tan, Z. Lou, W. Liao, X. Dong, Z. Zhu, W. Li, and Y. Chai Hydrophilic interaction and reversed-phase ultraperformance liquid chromatography TOF-MS for serum metabonomic analysis of myocardial infarction in rats and its applications Mol. Biosyst. 8 2012 548 556
31. H.G. Tiselius Epidemiology and medical management of stone disease BJU Int. 91 2003 758 767
32. J. Trygg, E. Holmes, and T. Lundstedt Chemometrics in metabonomics J. Proteome Res. 6 2007 469 479
33. T. Umekawa, N. Chegini, and S.R. Khan Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells Kidney Int. 61 2002 105 112
34. Y. Uwai, H. Honjo, and K. Iwamoto Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3 Pharmacol. Res. 65 2012 254 260
35. B.A. Young, M. Von Korff, S.R. Heckbert, E.J. Ludman, C. Rutter, E.H. Lin, P.S. Ciechanowski, M. Oliver, L. Williams, J. Himmelfarb, and W.J. Katon Association of major depression and mortality in stage 5 diabetic chronic kidney disease Gen. Hosp. Psychiatry 32 2010 119 124
36. Y.Y. Zhao, J. Liu, X.L. Cheng, X. Bai, and R.C. Lin Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS Clin. Chim. Acta 413 2012 642 649
37. Y.S. Zhong, C.H. Yu, H.Z. Ying, Z.Y. Wang, and H.F. Cai Prophylactic effects of Orthosiphon stamineus Benth. extracts on experimental induction of calcium oxalate nephrolithiasis in rats J. Ethnopharmacol. 144 2012 761 767